Cantor Fitzgerald Forecasts DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for Bright Minds Biosciences in a research note issued to investors on Wednesday, July 2nd. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will earn ($2.35) per share for the year, down from their previous forecast of ($0.64). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share. Cantor Fitzgerald also issued estimates for Bright Minds Biosciences’ FY2026 earnings at ($7.34) EPS.

Bright Minds Biosciences (NASDAQ:DRUG) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.10.

Several other research analysts also recently issued reports on the company. Wall Street Zen downgraded Bright Minds Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Cowen began coverage on shares of Bright Minds Biosciences in a research report on Tuesday, May 13th. They set a “buy” rating for the company. TD Cowen began coverage on shares of Bright Minds Biosciences in a research report on Tuesday, May 13th. They set a “buy” rating for the company. Finally, Chardan Capital reissued a “buy” rating and set a $80.00 target price on shares of Bright Minds Biosciences in a research report on Wednesday, May 21st. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Bright Minds Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $83.25.

Bright Minds Biosciences Price Performance

Bright Minds Biosciences stock opened at $28.30 on Friday. The business has a 50 day moving average of $29.00 and a 200-day moving average of $33.47. Bright Minds Biosciences has a 1 year low of $0.93 and a 1 year high of $79.02. The company has a market capitalization of $199.23 million, a P/E ratio of -78.61 and a beta of -6.01.

Institutional Trading of Bright Minds Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DRUG. Atika Capital Management LLC acquired a new stake in Bright Minds Biosciences during the 4th quarter valued at approximately $540,000. Springhill Fund Asset Management HK Co Ltd acquired a new stake in shares of Bright Minds Biosciences during the 4th quarter worth approximately $2,185,000. Walleye Capital LLC acquired a new stake in shares of Bright Minds Biosciences during the 4th quarter worth approximately $3,717,000. Vivo Capital LLC acquired a new stake in shares of Bright Minds Biosciences during the 4th quarter worth approximately $9,062,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Bright Minds Biosciences during the 4th quarter worth approximately $4,773,000. Institutional investors and hedge funds own 40.52% of the company’s stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.